Loading...
Market
Global sales of mRNA-1083 in first year post-approval
5
Resolution / Starting Odds
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Moderna's financial reports
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Stronger Immune Response in Phase 3 Trials
Jun 10, 2024, 11:10 AM
Moderna announced that its combination vaccine for COVID-19 and influenza generated a stronger immune response compared to separate shots against the two viruses. The investigational vaccine, mRNA-1083, showed positive results in a Phase 3 late-stage clinical trial, particularly in adults aged 50 and over. The Phase 3 data indicated that the combined vaccine is more effective than existing individual shots for both COVID-19 and flu. The company highlighted that the new vaccine could simplify immunization efforts by reducing the number of shots needed.
View original story
Similar markets
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Above $5 billion • 25%
Between $3 billion and $5 billion • 25%
Between $1 billion and $3 billion • 25%
Below $1 billion • 25%
Exceed $500 million • 25%
Between $300 million and $500 million • 25%
Between $100 million and $300 million • 25%
Below $100 million • 25%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Less than 50 million • 25%
50 to 100 million • 25%
100 to 200 million • 25%
More than 200 million • 25%
Acceleration in new mRNA vaccine entries • 25%
Stagnation due to legal uncertainties • 25%
Shift towards non-mRNA vaccine technologies • 25%
Increased legal battles over mRNA technologies • 25%
Spikevax • 33%
RSV vaccine • 33%
Other • 34%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%